Jason Zhu

Medical Oncologist at @LevineCancer Institute.

Formerly @DukeUBME, @EmoryUniversity, @dukemedicine, @DukeFellows

[Jason Zhu @TheRealJasonZhu]

@HemOncFellows @hemeoncfellow #Hemeonc #boardreview #Oncology #Hematology

[Jason Zhu @TheRealJasonZhu]

Side quest: https://t.co/5rHG9RdgiE

I built a FREE qbank! Check it out, share with friends, provide feedback.

✅ 2,000+ Med Onc questions
✅ 2,000+ Hematology questions
✅ Earn badges for milestones

#MedTwitter #OncTwitter #HemeTwitter @HemOncFellows

[Jason Zhu @TheRealJasonZhu]

@HemOncFellows And it's completely free at https://t.co/5tuUp5Ybaj.

No paywall. No trial period. No credit card.

If you're preparing for Heme/Onc boards or recertification, give it a try. And if it helps you — share it with your co-fellows.

[Earle Burgess @EarleFBurgess]

Why don’t all advanced prostate cancer patients with pathogenic homologous recombination repair (HRR) gene mutations respond to parp inhibitors?

Probably because the presence of HRR gene mutations does not always correlate with what is necessary for sensitivity to parp inhibitors = functional homologous recombination deficiency (HRD) in tumor cells.

Why do I say that?

Because that is what we found when our group looked at a large cohort of prostate cancer patients in collaboration with our colleagues at @TempusLabs.

Kudos to @LandonBrownMD, @TheRealJasonZhu and the Tempus team who did the heavy lifting for this project!

This is a really exciting paper. (I’m biased, I know.)

It suggests a functional assay of HRD may be a better biomarker to identify the prostate cancer patients who are most likely to respond to parp inhibitors than what we currently use in clinical practice (presence of HRR gene mutation).

Next step: design a clinical trial to test these findings!

Thank you Elizabeth Mauer, Stephanie Thiede, Lisa Macera, Michelle Stein, and Timothy J. Taxter at Tempus Labs for a great collaboration!

Pub:
https://t.co/McyGIJUR0i

[Tom Powles @tompowles1]

ctDNA positivity after cystectomy for muscle invasive bladder cancer identifies a high risk of relapse. These patients have a survival benefit with adjuvant atezolizumab. ctDNA-ve patients have low risk of relapse and don’t benefit from atezo. ctDNA clearance in ~20 #ESMOImmuno20

[Daniel Heng @DrDanielHeng]

Doubling PFS and ORR and HR 0.6 for OS. Cabozantinib+Nivolumab is now another standard of care for metastatic #kidneycancer. Reassuring that QOL data is improved too. So for Int/Poor risk patients, what combo would you choose? #oncoalert #ESMO2020

[CMC UROLOGY @CmcUrology]

Surgery Care Division Newsletter Spotlight on @CmcUrology
👇
GU Oncology Expansion to @AtriumHealth University

We are so excited to have Justin Matuly join the team!! 👏

@MDAndersonNews

[The ASCO Post @ASCOPost]

Neil Spector, MD, Physician-Scientist, Mentor, Author, Dies at 63 https://t.co/BcVKT0HZHT @DukeCancer

[Dr. Andy Wang 🇺🇦 @andyzwang]

Our latest work: Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy https://t.co/WCZ2ALDg5N. This is an alternative strategy to bi- and triapecific antibodies. #nkcell #cancerimmunotherapy @UNC_Lineberger @wang_unc @unchealth

[Jason Zhu @TheRealJasonZhu]

Could not have said it better. Has mentored generations of Duke residents and fellows. Generous with ideas, authorship, and most importantly time. Congratulations @TiansterZhang

[Matt Labriola @MattLabsMD]

Congrats @TiansterZhang for winning the @IMResidencyDuke Research Mentoring Award! Has had such a huge impact on my career and countless others! @TheRealJasonZhu @LandonBrownMD @Tucker_MatthewD @ChesterKao1

[Andrew Armstrong @AarmstrongDuke]

Check out our oral presentation today on a novel potential molecular predictor of immune checkpoint response across cancers: LRP1b! @DukeGUCancer great job @LandonBrownMD https://t.co/R2qG2m5hwT and discussion https://t.co/vzIo6wu7f0 #ASCO2020 @TheRealJasonZhu